Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447170 | 0.94 | PDE5A (0.78) | PDE5APDE6C | |
| SCHEMBL6446371 | 0.94 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL6443633 | 0.94 | PDE5A (0.87) | PDE5APDE6C | |
| SCHEMBL6631665 | 0.94 | PDE5A (0.78) | PDE5APDE6C | |
| SCHEMBL6444669 | 0.94 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL6446034 | 0.94 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL6443363 | 0.93 | PDE5A (0.83) | PDE5APDE6C | |
| SCHEMBL29419599 | 0.93 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6441935 | 0.93 | PDE5A (0.83) | PDE5APDE6C | |
| SCHEMBL314617 | 0.93 | PDE5A (1.00) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1220855-B1 | ANHYDROUS SALT | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | claimed |
| EP-1220855-A2 | ANHYDROUS SALT | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | claimed |
| US-6350751-B1 | ANHYDROUS PARA-TOLUENESULPHONIC ACID SALTS OF 3-ETHYL-5-(5-(4-ETHYL PIPERAZIN-1-YLSULPHONYL)-2-(2-METHOXYETHOXY) PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)METHYL-2,6-DIHYDRO-7H-PYRAZOLO | PFIZER INC. | 2002-02-26 | — | — | US | claimed |
| WO-2001027101-A2 | ANHYDROUS SALT | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | claimed |
| US-7067660-B2 | such as 1-(4-ethoxy-3-formylphenylsulfonyl)-4-methylpiperazine; for use as anti-impotence agent | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1092720-B1 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1296983-B1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LTD (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040110948-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| EP-1220855-B1 | ANHYDROUS SALT | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6730786-B2 | REACTING A BENZAMIDINE COMPOUND WITH A AMIDE SUBSTITUTED PYRAZOLE COMPOUND | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-6350751-B1 | ANHYDROUS PARA-TOLUENESULPHONIC ACID SALTS OF 3-ETHYL-5-(5-(4-ETHYL PIPERAZIN-1-YLSULPHONYL)-2-(2-METHOXYETHOXY) PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)METHYL-2,6-DIHYDRO-7H-PYRAZOLO | PFIZER INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 21/4885 |
| US-20020013465-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | PDE5A 1679/4885PDE6C 3203/4885 |
| US-20040110948-A1 | Novel process for the preparation of pyrazolopyrimidinones | SDHA, NDUFS3, NDUFS2 | PDE5A 1679/4885PDE6C 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.